$0.4928
-0.0335-6.37%
Last update: Nov 10, 4:01 AM
Citius Pharmaceuticals Inc
CTXRNASDAQ
Citius Pharmaceuticals fell 58.9% from $1.28 to $0.53, behind the S&P 500's +10.0%. Its worst day was Aug 17 (−25.6%), and its low came Oct 22 at $0.37.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Citius Pharmaceuticals closed at its highest level of the year, 12.5% above where the year started.
+2.9% · S&P 500 +0.5%
EPS of $-0.11 beat the $-0.24 estimate on $0.00 revenue (est. $5.8M).
Story events cover the past 12 months · Times ET
−23.0%, on 19M shares, the year's heaviest volume · S&P 500 +0.4%
EPS of $-0.38 missed the $-0.30 estimate on $3.9M revenue (est. $3.5M).
−3.6% · S&P 500 +0.1%
Citius Pharmaceuticals shares rose 32.3%, while the S&P 500 rose 2.9%.
+32.3%, the year's best day · S&P 500 +2.9%
Citius Pharmaceuticals (NASDAQ:CTXR) shares tumbled on Friday after it announced a registered direct offering, raising dilution concerns.
−17.5% · S&P 500 +0.8%
EPS of $-0.99 missed the $-0.32 estimate on $1.7M revenue (est. $9.9M).
−24.8% · S&P 500 −0.1%
Citius Pharmaceuticals shares rose 25.4%, while the S&P 500 fell 0.2%.
+25.4% · S&P 500 −0.2%
EPS of $-0.34 beat the $-0.36 estimate on $1.5M revenue (est. $5.5M).
−25.6%, the year's worst day · S&P 500 −0.5%
Citius Pharmaceuticals closed at its lowest level of the year, 71.0% below where the year started.
−6.2% · S&P 500 −1.2%
Where it ended: a close of $0.53 on Nov 9, 2026. Up next: Q4 2026 earnings on Dec 22, 2026 (EPS est. $-0.41, revenue est. $2.9M).
Nothing in the past 12 months.
All CTXR dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CTXR and SPY from Benzinga historical bars. Not investment advice.
